Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is to be performed as an open label, multicenter, single arm study of 2X-121 to
evaluate anti-tumor efficacy of 2X-121 as single agent therapy in a 28-days cycle in advanced
ovarian cancer patients. 2X-121 will be supplied for oral administration once daily as 600 mg
(3 x 200 mg) capsules in a 28 days cycle. Patients with predicted high likelihood of
responding to the drug (2X-121) using drug response prediction (DRP®), will be included in
the study.